🔗 Share this article

Given that the US undertakes sweeping changes to its vaccine schedules, an unexpected name appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who first made her name by questioning COVID-19 vaccinations throughout the global health crisis and has concentrated on possible fatalities after Covid immunization in her recent position at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Immunization Schedule

Health officials planned to reveal major changes to the pediatric vaccine schedule earlier this month, bringing the US with the Danish immunization schedule, sources say – a significant shift that would put the US at odds with many the world with little proof for improved outcomes. This reveal has been pushed back until the new year.

Instead of Vinay Prasad, Dr. Høeg is listed to speak at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth individual to run the division this year.

Consolidating Power at the Agency

The acting appointment could signify a strengthened alliance between the drug and biologics centers as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon rolling back long-standing immunizations at the FDA.

The new acting director has frequently advocated for ending specific childhood vaccine recommendations in the US so as to align more in line with Denmark's approach, a nation with comprehensive healthcare and a population approximately the population of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccines – usually the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Questions Over Qualifications

Høeg has no apparent background in drug development, approval processes or leadership, which has been standard for past directors of the biologics center. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in leading a major agency. She lacks background in industry regulation.”

Previous directors of the center would “be deeply familiar with legal statutes and the research of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she doesn’t have the type of experience that former directors who ran the center have had.”

CDER has an enormous workload at the FDA, she stated.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office approves numerous generic drugs. There’s a biologic copycat branch, OTC medication office and other areas, and all of those have to be supervised,” she noted. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”

Furthermore, a major administrative component to the job, which manages over 5,000 staff members. “It is a massive management job, if you do it right,” she concluded.

Response and Controversial Policies

Regarding inquiries about Dr. Høeg's fitness for the role and whether this appointment represents increased cooperation among FDA leaders on vaccines, a representative responded that the “concerns rely on inaccurate premises”.

“Her resume is consistent with the duties of her role,” the spokesperson explained, citing the time Dr. Høeg spent guiding the FDA commissioner on “drug safety and approval science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s new priority voucher program, a controversial rapid medication authorization process that reportedly worried her former heads. “How are these drugs being picked for this fast-track system? Who takes the decisions?” Howard questioned. “There is a lot of confidentiality happening at the agency right now.”

Overall, he said, “the agency seems to be moving towards more relaxed rules of pharmaceuticals, aside from immunizations.”

Public History on Vaccines

Concerning immunizations, Høeg has a clearer, if problematic, history, critics said. She published a study using unconfirmed volunteer-provided data to estimate the frequency of heart inflammation after Covid vaccination. She advised the Florida top health official Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the new government encompassed changing regulations for novel immunizations and halting “optional” vaccines, she stated after the election on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of barring teenage boys from obtaining Covid vaccines.

“She is an complete true believer who starts off with her conclusions and tailors the evidence to accommodate the evidence in a extremely disingenuous, fraudulent way,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|